Earnings ·
Embecta Corp. reported third-quarter fiscal 2026 results for the period ended June 30, 2026, announcing a quarterly…
EMBCEmbecta Corp.
Embecta Corp. reported third-quarter fiscal 2026 results for the period ended June 30, 2026, announcing a quarterly cash dividend of $0.01 per share payable on September 15, 2026 to holders of record as of August 27, 2026. Reported revenues decreased 8.1% year-over-year to $271.7 million, driven by a 24.6% decline in U.S. sales, partially offset by an 11.5% increase in International revenue and contributions from the Owen Mumford acquisition. The company raised its full-year adjusted operating margin guidance to 23.50%-24.00% and adjusted EPS guidance to $1.80-$1.90, while reaffirming revenue guidance of $1.015 billion-$1.035 billion. Embecta operates in the diabetes care industry, manufacturing medical devices such as pen needles and syringes.